Topical 15% zinc oxide ointment significantly reduces the size of common warts after 4 weeks’ application: a randomized, triple-blinded, placebo-controlled trial
- Conditions
- palmar warts or verruca vulgaris
- Registration Number
- TCTR20180523001
- Lead Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 16
Patients older than 18 years with at least 2 similar palmar warts or verruca vulgaris on either one or both hands were eligible. The wart diameter had to range between 2 to 8 millimeters, the total number of lesions had to be at least 2 but not more than 15 and they must have never been treated with any zinc preparations.
Subjects who had recalcitrant warts which were defined as warts unresponsive to any treatment at least 5 times in the past 6 months, those who had known allergy to any formulation of zinc, or categorized as immunocompromised host, e.g. poorly-controlled diabetes mellitus, acquired immunodeficiency syndrome (AIDS), chronic kidney disease, or were treated with immunosuppressive agents by topical or systemic treatment, as well as pregnant or lactating women were excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method size of the lesion (surface area) week 0, 2 and 4 photograph by dermoscopy and analyzed by illustrator CS6
- Secondary Outcome Measures
Name Time Method Side effect of topical 15% zinc oxide week 0, 2 and 4 case record form,diameter of the lesion week 0, 2 and 4 photograph by dermoscopy and analyzed by illustrator CS6,volume of the lesion week 0, 2 and 4 Antera camera 3D,patients and physician assessment week 4 score from questionnaire